Mutovina Zyu 1

1. Efficacy of olokizumab in patients with mild or moderate COVID-19 and risk factors of progression moderate
2. Vasculitis with nervous system damage in a patient with adenosine deaminase 2 deficiency
3. Still’s disease in a patient with common variable immunodeficiency: NFKB1 defect
1